The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Evidence · Trials · continued

Coming back to: Sample size calculations, read backwards from the published number posts 31–60

This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.

BI
blank_injectionTL2Analytical chemist26 May 2025#31

Understood. Thank you for being specific about the limits of it.

25 likes 14mo
HI
h.iyerTL229 May 2025#32

If someone has run Sample size calculations properly I would rather read that than my own reconstruction of it. Posting mine only because the thread has gone quiet.

12 likes 14mo
PI
p.iyer_pharmdTL3Pharmacist31 May 2025 · edited#33

Agreed on Sample size calculations, with one qualification that I think matters. The reasoning holds for the case as described. Change the starting assumption and it does not, and the starting assumption is the part nobody states.

4 likes 14mo
CO
c.ostergaardTL22 Jun 2025#34
l.ibarra, post #19: I would keep Sample size calculations and the decision it usually gets used for separate in this thread. They are related and they are not the same question, and merging them is why the last one went badly. Go to post

Narrowing post #33, because the general version has more than one answer.

Absolute and relative effects answer different questions. Write down the event rate in each arm and the difference between them; everything quotable is derived from those two numbers.

0 likes in reply to #19 14mo
QZ
q.zhao_qaTL3Quality assurance4 Jun 2025#35
t.varga, post #5: Post #2 answers the question as asked. The question underneath it is different. Nobody has said the unglamorous part of Sample size calculations yet, so: most of the variation is explained by things that are boring to write about and easy to check. Go to post

Worth separating two things that post #33 runs together.

Composite endpoints should be read component by component. A composite driven entirely by its softest component is a different finding from one where the components move together.

0 likes in reply to #5 14mo
SA
s.antonsenTL26 Jun 2025#36

This follows post #33 rather than contradicting it.

A methods point on Sample size calculations rather than a substantive one: if the comparison is not like for like, the difference you are measuring is the difference in method.

18 likes 14mo
FP
forest_plotTL3Evidence synthesis8 Jun 2025#37

Two people in this thread mean different things by Sample size calculations and are disagreeing about the definition while believing they are disagreeing about the facts. Worth pausing to define it.

7 likes 14mo
NV
n.villalobosTL210 Jun 2025#38
TW
t.wojcikTL212 Jun 2025 · edited#39
y.rahimi, post #18: A treatment-policy estimand asks what happens to people assigned to a strategy, including those who abandon it. A hypothetical estimand asks what would have happened had everyone continued. Both are legitimate and they give different numbers. Adding the caveat now so it does not have to be extracted later. Go to post

I would put moderate confidence on the mainstream reading of Sample size calculations and no more. That is not scepticism for its own sake; it is where the sourcing actually stops.

0 likes in reply to #18 14mo
JD
j.dahlbergTL214 Jun 2025#40

Noted, and thank you for writing it out rather than summarising it.

24 likes 13mo
DY
d.yilmazTL216 Jun 2025#41
y.rahimi, post #18: A treatment-policy estimand asks what happens to people assigned to a strategy, including those who abandon it. A hypothetical estimand asks what would have happened had everyone continued. Both are legitimate and they give different numbers. Adding the caveat now so it does not have to be extracted later. Go to post

An update on my earlier Sample size calculations post: the pattern held for another six weeks and then stopped, which I did not predict and cannot explain.

33 likes in reply to #18 13mo
ML
m.lindqvistTL218 Jun 2025#42
CF
c.falkTL220 Jun 2025#43

The strongest argument against my own position on Sample size calculations, stated as well as I can state it, since nobody else has yet.

7 likes 13mo
AW
a.westergaardTL3Regular21 Jun 2025#44

Answering the question post #41 raises rather than the one it answers.

What I would tell a new member reading about Sample size calculations for the first time: the confident posts are not the reliable ones, and the reliable ones are longer.

17 likes 13mo
NN
n.nybergTL223 Jun 2025#45

Risk of bias: structured appraisal of internal validity. Key things to assess: randomisation method (was it truly random or could someone predict the next assignment), concealment (could randomisation be subverted), blinding (who was blinded and why or why not), completeness of outcome reporting.

24 likes 13mo
ML
m.lehtinenTL225 Jun 2025 · edited#46
q.zhao_qa, post #35: Worth separating two things that post #33 runs together. Composite endpoints should be read component by component. A composite driven entirely by its softest component is a different finding from one where the components move together. Go to post

No disagreement from me. Posting only so the question does not look ignored.

0 likes in reply to #35 13mo
RR
r.restrepoTL227 Jun 2025#47

Adding the measurement that post #45 says would settle it.

I think the Sample size calculations question is answerable and has not been answered, which is a more optimistic position than most of this thread.

3 likes 13mo
CL
c.lundgrenTL229 Jun 2025#48

Post #44 describes the usual case. This is about the unusual one.

Where the Sample size calculations reasoning breaks down for me is the step from the group result to the individual case. That step is almost never argued for.

11 likes 13mo
TB
t.brandtTL21 Jul 2025#49
DM
d.magalhesTL2Member3 Jul 2025#50

Worth separating two things that post #48 runs together.

Small methodological point on Sample size calculations: repeating a measurement is cheap and resolves most of what is being argued about here at no cost to anyone.

16 likes 13mo
TH
TL4_HalvorsenTL4Leader · Journal club5 Jul 2025#51

Sample size calculations: I would want to see the raw numbers rather than the summary before agreeing. Summaries lose exactly the information that would settle this.

23 likes 13mo
RE
r.ekstromTL27 Jul 2025#52

Absolute and relative effects answer different questions. Write down the event rate in each arm and the difference between them; everything quotable is derived from those two numbers.

That matches what I was told, which is not the same as knowing it.

10 likes 13mo
FN
formulary_notesTL3Regular8 Jul 2025#53

Post #51 describes the usual case. This is about the unusual one.

Number needed to treat is only interpretable with the duration attached. The same NNT over one year and over five years describes very different clinical situations.

Anyone who has looked at this more carefully, please correct the record.

1 like 13mo
HL
h.lindqvistTL210 Jul 2025#54
a.kirchner, post #20: The practical version of Sample size calculations is three sentences long. The rigorous version is three pages and reaches the same conclusion with the conditions attached. Go to post

Adding the measurement that post #51 says would settle it.

The claim about Sample size calculations upthread is stronger than its source supports. I have read the source. The source says "associated with" and the post says "causes".

0 likes in reply to #20 13mo
C
chromatogramTL4Analytical chemist12 Jul 2025#55

I would be cautious about generalising from the Sample size calculations example above. It is a good example. It is one example.

31 likes 13mo
AW
a.wikstromTL214 Jul 2025#56

Absolute numbers, not just relative: a 30% relative reduction tells you the ratio but not the practical magnitude. The event rate in each arm and the difference between them tells you how many people benefit.

15 likes 12mo
EF
endo_fellow_rkTL3Endocrinology fellow16 Jul 2025#57

Two sentences on Sample size calculations and then I will stop, because the rest is speculation and the thread is better without mine.

What is documented is narrow. What is inferred from it is broad. The gap between them is where every argument here lives.

3 likes 12mo
TD
t.dumitruTL218 Jul 2025#58
preregistered, post #15: Where I part company with post #11, and it is a narrow parting. Number needed to treat is only interpretable with the duration attached. The same NNT over one year and over five years describes very different clinical situations. Go to post

Picking up post #55: that is the part I would want checked first.

Discontinuation handling is the methodological detail that most changes a result and gets the least attention. Read how missing data was imputed before reading the effect size.

Same conclusion as the reply above, reached differently, which is mildly reassuring.

0 likes in reply to #15 12mo
CB
c.bakkerTL219 Jul 2025 · edited#59
chromatogram, post #55: I would be cautious about generalising from the Sample size calculations example above. It is a good example. It is one example. Go to post

Post #55 put the caveat in the right place and I want to underline it.

Something worth flagging about Sample size calculations: the strongest-sounding claims in this thread are the ones with no source attached, which is the usual pattern and not a coincidence.

0 likes in reply to #55 12mo
JN
j.nascimentoTL221 Jul 2025#60

Building on post #59 rather than restating it.

The documentation on Sample size calculations is better than this thread and I say that as someone who has posted in the thread.

22 likes 12mo